Converging and diverging properties of human interleukin-4 and interleukin-10.
IL-4 and IL-10 are both produced by activated TH2 cells as well as basophil/mast cells. In addition, IL-10 is secreted by activated B cells, monocytes/macrophages and keratinocytes. IL-4 and IL-10 act in concert to induce activated B lymphocytes to grow, switch isotype and ultimately differentiate into antibody producing plasma cells. Both IL-4 and IL-10 inhibit the secretion of proinflammatory cytokines by monocytes/macrophages and neutrophils. While IL-4 enhances the presentation of antigen by monocytes/macrophages and dendritic cells, IL-10 inhibits it. IL-4 and IL-10 can either stimulate or inhibit T cell proliferation. While both cytokines may prove useful in the management of inflammatory disorders, IL-4 is presently used in clinical trials that relate to its antitumor effects.
Banchereau
J
J
Laboratoire de Recherches Immunologiques, Schering-Plough, Dardilly, France.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D015551:Autoimmunity; D001402:B-Lymphocytes / Q000276:immunology*; D001491:Basophils / Q000276:immunology; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D006967:Hypersensitivity; D007108:Immune Tolerance; D016753:Interleukin-10 / Q000096:biosynthesis / Q000494:pharmacology / Q000502:physiology*; D015847:Interleukin-4 / Q000096:biosynthesis / Q000494:pharmacology / Q000502:physiology*; D008407:Mast Cells / Q000276:immunology; D051379:Mice; D018448:Models, Immunological; D010954:Plasmacytoma / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D016753:Interleukin-10; D015847:Interleukin-4